Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus capecitabine versus cisplatin plus capecitabine in triple-negative breast cancer
ChiCTR-IIR-17010716Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Mar 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Gemcitabine plus capecitabine (GX regimen) with Cisplatin plus capecitabine (CX regimen) (2 arms). Primary endpoint: Response rate. Started Mar 2017; status: recruiting.
02
Drugs
gemcitabinecapecitabinecisplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR-IIR-17010716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17010716.